These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

276 related items for PubMed ID: 12097269

  • 1. Raloxifene, a selective estrogen receptor modulator, induces apoptosis in androgen-responsive human prostate cancer cell line LNCaP through an androgen-independent pathway.
    Kim IY, Seong DH, Kim BC, Lee DK, Remaley AT, Leach F, Morton RA, Kim SJ.
    Cancer Res; 2002 Jul 01; 62(13):3649-53. PubMed ID: 12097269
    [Abstract] [Full Text] [Related]

  • 2. Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines.
    Kim IY, Kim BC, Seong DH, Lee DK, Seo JM, Hong YJ, Kim HT, Morton RA, Kim SJ.
    Cancer Res; 2002 Sep 15; 62(18):5365-9. PubMed ID: 12235008
    [Abstract] [Full Text] [Related]

  • 3. Interruption of nuclear factor kappaB signaling by the androgen receptor facilitates 12-O-tetradecanoylphorbolacetate-induced apoptosis in androgen-sensitive prostate cancer LNCaP cells.
    Altuwaijri S, Lin HK, Chuang KH, Lin WJ, Yeh S, Hanchett LA, Rahman MM, Kang HY, Tsai MY, Zhang Y, Yang L, Chang C.
    Cancer Res; 2003 Nov 01; 63(21):7106-12. PubMed ID: 14612503
    [Abstract] [Full Text] [Related]

  • 4. Raloxifene induces cell death and inhibits proliferation through multiple signaling pathways in prostate cancer cells expressing different levels of estrogen receptor α and β.
    Rossi V, Bellastella G, De Rosa C, Abbondanza C, Visconti D, Maione L, Chieffi P, Della Ragione F, Prezioso D, De Bellis A, Bellastella A, Sinisi AA.
    J Cell Physiol; 2011 May 01; 226(5):1334-9. PubMed ID: 20945400
    [Abstract] [Full Text] [Related]

  • 5. A novel dietary triterpene Lupeol induces fas-mediated apoptotic death of androgen-sensitive prostate cancer cells and inhibits tumor growth in a xenograft model.
    Saleem M, Kweon MH, Yun JM, Adhami VM, Khan N, Syed DN, Mukhtar H.
    Cancer Res; 2005 Dec 01; 65(23):11203-13. PubMed ID: 16322271
    [Abstract] [Full Text] [Related]

  • 6. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
    Zhu ML, Partin JV, Bruckheimer EM, Strup SE, Kyprianou N.
    Prostate; 2008 Feb 15; 68(3):287-95. PubMed ID: 18163430
    [Abstract] [Full Text] [Related]

  • 7. Androgen receptor-dependent and -independent mechanisms mediate Ganoderma lucidum activities in LNCaP prostate cancer cells.
    Zaidman BZ, Wasser SP, Nevo E, Mahajna J.
    Int J Oncol; 2007 Oct 15; 31(4):959-67. PubMed ID: 17786330
    [Abstract] [Full Text] [Related]

  • 8. C-Jun N-terminal kinase is required for phorbol ester- and thapsigargin-induced apoptosis in the androgen responsive prostate cancer cell line LNCaP.
    Engedal N, Korkmaz CG, Saatcioglu F.
    Oncogene; 2002 Feb 07; 21(7):1017-27. PubMed ID: 11850819
    [Abstract] [Full Text] [Related]

  • 9. Apoptosis of human prostate androgen-dependent and -independent carcinoma cells induced by an isopropanolic extract of black cohosh involves degradation of cytokeratin (CK) 18.
    Hostanska K, Nisslein T, Freudenstein J, Reichling J, Saller R.
    Anticancer Res; 2005 Feb 07; 25(1A):139-47. PubMed ID: 15816531
    [Abstract] [Full Text] [Related]

  • 10. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
    Unni E, Sun S, Nan B, McPhaul MJ, Cheskis B, Mancini MA, Marcelli M.
    Cancer Res; 2004 Oct 01; 64(19):7156-68. PubMed ID: 15466214
    [Abstract] [Full Text] [Related]

  • 11. Protection of androgen-dependent human prostate cancer cells from oxidative stress-induced DNA damage by overexpression of clusterin and its modulation by androgen.
    Miyake H, Hara I, Gleave ME, Eto H.
    Prostate; 2004 Dec 01; 61(4):318-23. PubMed ID: 15389725
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms.
    Tepper CG, Vinall RL, Wee CB, Xue L, Shi XB, Burich R, Mack PC, de Vere White RW.
    Prostate; 2007 Apr 01; 67(5):521-35. PubMed ID: 17252539
    [Abstract] [Full Text] [Related]

  • 14. Concentration-dependent effects of a selective estrogen receptor modulator raloxifene on proliferation and apoptosis in human uterine leiomyoma cells cultured in vitro.
    Liu J, Matsuo H, Xu Q, Chen W, Wang J, Maruo T.
    Hum Reprod; 2007 May 01; 22(5):1253-9. PubMed ID: 17220163
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. ERRgamma suppresses cell proliferation and tumor growth of androgen-sensitive and androgen-insensitive prostate cancer cells and its implication as a therapeutic target for prostate cancer.
    Yu S, Wang X, Ng CF, Chen S, Chan FL.
    Cancer Res; 2007 May 15; 67(10):4904-14. PubMed ID: 17510420
    [Abstract] [Full Text] [Related]

  • 19. Phorbol ester-induced apoptosis is accompanied by NGFI-A and c-fos activation in androgen-sensitive prostate cancer cells.
    Day ML, Zhao X, Wu S, Swanson PE, Humphrey PA.
    Cell Growth Differ; 1994 Jul 15; 5(7):735-41. PubMed ID: 7947388
    [Abstract] [Full Text] [Related]

  • 20. Raloxifene, an oestrogen-receptor-beta-targeted therapy, inhibits androgen-independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial.
    Shazer RL, Jain A, Galkin AV, Cinman N, Nguyen KN, Natale RB, Gross M, Green L, Bender LI, Holden S, Kaplan L, Agus DB.
    BJU Int; 2006 Apr 15; 97(4):691-7. PubMed ID: 16536755
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.